Towards a gene therapy for age-related macular degeneration (AMD)

Project description

Addressing barrier integrity issues in the treatment of age-related macular degeneration

The macula is the part of the eye that is responsible for central vision. Damage to the macula can gradually occur as an individual ages, resulting in vision problems that significantly impact daily life. Research into age-related macular degeneration (AMD) has shown that disrupted endothelial barrier integrity is a significant driving force behind this condition. Based on this discovery, scientists of the EU-funded Opti-AAV project are working towards a novel therapy approach for AMD that involves the local delivery of exosome-encapsulated endothelial cell-specific adeno-associated virus into the blood–retina barrier. The aim is to enable the efficient transduction of retinal endothelial cells, thus preventing the progression of the disease.

Fields of science

• medical and health sciences › medical biotechnology › genetic engineering › gene therapy
• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › clinical medicine › ophthalmology
• medical and health sciences › basic medicine › pathology

Programme(s)

• HORIZON.1.1 - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2022-POC1 - ERC PROOF OF CONCEPT GRANTS1

Call for proposal

ERC-2022-POC1

See other projects for this call

Funding Scheme

ERC-POC - Proof of Concept Grant

Coordinator

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Net EU contribution

€ 150 000,00

Address

College Green Trinity College
D02 CX56 Dublin 2
Ireland

Region

Ireland › Eastern and Midland › Dublin

Activity type

Higher or Secondary Education Establishments

Links

Other funding

No data